Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod
I. Costedoat(Hôpital Saint-André), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), S. Prey(Université de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), E. Gérard(Université de Bordeaux), L. Dousset(Centre Hospitalier Universitaire de Bordeaux), Rémi Vergara(Université de Bordeaux), M. Beylot‐Barry(Université de Bordeaux)
Cited by 3
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k